Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
13
05
2022
accepted:
11
07
2022
revised:
06
07
2022
pubmed:
5
8
2022
medline:
31
8
2022
entrez:
4
8
2022
Statut:
ppublish
Résumé
In immune aplastic anemia (IAA), severe pancytopenia results from the immune-mediated destruction of hematopoietic stem cells. Several autoantibodies have been reported, but no clinically applicable autoantibody tests are available for IAA. We screened autoantibodies using a microarray containing >9000 proteins and validated the findings in a large international cohort of IAA patients (n = 405) and controls (n = 815). We identified a novel autoantibody that binds to the C-terminal end of cyclooxygenase 2 (COX-2, aCOX-2 Ab). In total, 37% of all adult IAA patients tested positive for aCOX-2 Ab, while only 1.7% of the controls were aCOX-2 Ab positive. Sporadic non-IAA aCOX-2 Ab positive cases were observed among patients with related bone marrow failure diseases, multiple sclerosis, and type I diabetes, whereas no aCOX-2 Ab seropositivity was detected in the healthy controls, in patients with non-autoinflammatory diseases or rheumatoid arthritis. In IAA, anti-COX-2 Ab positivity correlated with age and the HLA-DRB1*15:01 genotype. 83% of the >40 years old IAA patients with HLA-DRB1*15:01 were anti-COX-2 Ab positive, indicating an excellent sensitivity in this group. aCOX-2 Ab positive IAA patients also presented lower platelet counts. Our results suggest that aCOX-2 Ab defines a distinct subgroup of IAA and may serve as a valuable disease biomarker.
Identifiants
pubmed: 35927326
doi: 10.1038/s41375-022-01654-6
pii: 10.1038/s41375-022-01654-6
pmc: PMC9417997
doi:
Substances chimiques
Autoantibodies
0
Biomarkers
0
HLA-DRB1 Chains
0
Cyclooxygenase 2
EC 1.14.99.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2317-2327Informations de copyright
© 2022. The Author(s).
Références
Young NS. Aplastic anemia. N Engl J Med. 2018;379:1643–56.
pubmed: 30354958
pmcid: 6467577
doi: 10.1056/NEJMra1413485
Locasciulli A, Arcese W, Locatelli F, Di Bona E, Bacigalupo A. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Lancet. 2001;357:43–4.
pubmed: 11197365
doi: 10.1016/S0140-6736(00)03574-1
Ohara A, Kojima S, Hamajima N, Tsuchida M, Imashuku S, Ohta S, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90:1009–13.
pubmed: 9242530
doi: 10.1182/blood.V90.3.1009
Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100:786–90.
pubmed: 12130487
doi: 10.1182/blood.V100.3.786
Nakao S, Takamatsu H, Chuhjo T, Ueda M, Shiobara S, Matsuda T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994;84:4257–61.
pubmed: 7994040
doi: 10.1182/blood.V84.12.4257.bloodjournal84124257
Führer M, Durner J, Brünnler G, Götte H, Deppner C, Bender‐Götze C, et al. HLA association is different in children and adults with severe acquired aplastic anemia. Pediatr Blood Cancer. 2007;48:186–91.
pubmed: 16496287
doi: 10.1002/pbc.20785
Maciejewski JP, Follmann D, Nakamura R, Saunthararajah Y, Rivera CE, Simonis T, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood. 2001;98:3513–9.
pubmed: 11739151
doi: 10.1182/blood.V98.13.3513
Narita A, Kojima S. Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia. Int J Hematol. 2016;104:153–8.
pubmed: 27091471
doi: 10.1007/s12185-016-2009-z
Vaht K, Göransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011. Haematologica. 2017;102:1683–90.
pubmed: 28751565
pmcid: 5622852
doi: 10.3324/haematol.2017.169862
Zoumbos NC, Gascón P, Djeu JY, Trost SR, Young NS. Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med. 1985;312:257–65.
pubmed: 2981406
doi: 10.1056/NEJM198501313120501
Hosokawa K, Muranski P, Feng X, Townsley DM, Liu B, Knickelbein J, et al. Memory stem T cells in autoimmune disease: high frequency of circulating CD8+ memory stem cells in acquired aplastic anemia. J Immunol. 2016;196:1568–78.
pubmed: 26764034
doi: 10.4049/jimmunol.1501739
Kordasti S, Costantini B, Seidl T, Perez Abellan P, Martinez Llordella M, McLornan D, et al. Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood. 2016;128:1193–205.
pubmed: 27281795
pmcid: 5009512
doi: 10.1182/blood-2016-03-703702
Li H, Wang L, Pang Y, Jiang Z, Liu Z, Xiao H, et al. In patients with chronic aplastic anemia, bone marrow-derived MSCs regulate the Treg/Th17 balance by influencing the Notch/RBP-J/FOXP3/RORγt pathway. Sci Rep. 2017;7:42488.
pubmed: 28195151
pmcid: 5307358
doi: 10.1038/srep42488
Afable MG, Wlodarski M, Makishima H, Shaik M, Sekeres MA, Tiu RV, et al. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood. 2011;117:6876–84.
pubmed: 21527527
pmcid: 3128479
doi: 10.1182/blood-2010-11-314393
Katagiri T, Sato-Otsubo A, Kashiwase K, Morishima S, Sato Y, Mori Y, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011;118:6601–9.
pubmed: 21963603
doi: 10.1182/blood-2011-07-365189
Zaimoku Y, Takamatsu H, Hosomichi K, Ozawa T, Nakagawa N, Imi T, et al. Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia. Blood. 2017;129:2908–16.
pubmed: 28232583
doi: 10.1182/blood-2016-11-752378
Betensky M, Babushok D, Roth JJ, Mason PJ, Biegel JA, Busse TM, et al. Clonal evolution and clinical significance of copy number neutral loss of heterozygosity of chromosome arm 6p in acquired aplastic anemia. Cancer Genet. 2016;209:1–10.
pubmed: 26702937
doi: 10.1016/j.cancergen.2015.10.002
Imi T, Katagiri T, Hosomichi K, Zaimoku Y, Hoang Nguyen V, Nakagawa N, et al. Sustained clonal hematopoiesis by HLA-lacking hematopoietic stem cells without driver mutations in aplastic anemia. Blood Adv. 2018;2:1000–12.
pubmed: 29720492
pmcid: 5941997
doi: 10.1182/bloodadvances.2017013953
Elbadry MI, Mizumaki H, Hosokawa K, Espinoza JL, Nakagawa N, Chonabayashi K, et al. Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anemia. Haematologica. 2019;104:e447–50.
pubmed: 30890597
pmcid: 6886421
doi: 10.3324/haematol.2018.210856
Espinoza JL, Elbadry MI, Chonabayashi K, Yoshida Y, Katagiri T, Harada K, et al. Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack. Blood Adv. 2018;2:390–400.
pubmed: 29472446
pmcid: 5858477
doi: 10.1182/bloodadvances.2017013342
Hirano N. Autoantibodies frequently detected in patients with aplastic anemia. Blood. 2003;102:4567–75.
pubmed: 12947009
doi: 10.1182/blood-2002-11-3409
Hirano N, Butler MO, Guinan EC, Nadler LM, Kojima S. Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br J Haematol. 2005;128:221–3.
pubmed: 15638857
doi: 10.1111/j.1365-2141.2004.05317.x
Feng X. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2004;104:2425–31.
pubmed: 15217832
doi: 10.1182/blood-2004-05-1839
Jankovicova B, Skultety L, Dubrovcakova M, Stern M, Bilkova Z, Lakota J. Overlap of epitopes recognized by anti-carbonic anhydrase I IgG in patients with malignancy-related aplastic anemia-like syndrome and in patients with aplastic anemia. Immunol Lett. 2013;153:47–9.
pubmed: 23892086
doi: 10.1016/j.imlet.2013.07.006
Lakota J, Lanz A, Dubrovcakova M, Jankovicova B, Gonzalez A, Stern M. Antibodies against carbonic anhydrase in patients with aplastic anemia. Acta Haematol. 2012;128:190–4.
pubmed: 22889718
doi: 10.1159/000338826
Qi Z, Takamatsu H, Espinoza JL, Lu X, Sugimori N, Yamazaki H, et al. Autoantibodies specific to hnRNP K: a new diagnostic marker for immune pathophysiology in aplastic anemia. Ann Hematol. 2010;89:1255–63.
pubmed: 20623123
doi: 10.1007/s00277-010-1020-3
Goto M, Kuribayashi K, Takahashi Y, Kondoh T, Tanaka M, Kobayashi D, et al. Identification of autoantibodies expressed in acquired aplastic anaemia. Br J Haematol. 2013;160:359–62.
pubmed: 23116149
doi: 10.1111/bjh.12116
Takamatsu H, Feng X, Chuhjo T, Lu X, Sugimori C, Okawa K, et al. Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia. Blood. 2007;109:2514–20.
pubmed: 17110458
doi: 10.1182/blood-2006-07-036715
Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172:187–207.
pubmed: 26568159
doi: 10.1111/bjh.13853
Hamano Y, Kida H, Ihara S, Murakami A, Yanagawa M, Ueda K, et al. Classification of idiopathic interstitial pneumonias using anti–myxovirus resistance-protein 1 autoantibody. Sci Rep. 2017;7:1–15.
doi: 10.1038/srep43201
Chang C, Hsieh M-K, Chang W-Y, Chiang AJ, Chen J. Determining the optimal number and location of cutoff points with application to data of cervical cancer. PLoS ONE. 2017;12:e0176231.
pubmed: 28448533
pmcid: 5407800
doi: 10.1371/journal.pone.0176231
López-Ratón M, Rodriguez-Alvarez MX, Cadarso-Suárez C, Gude-Sampedro F. OptimalCutpoints: R Package Selecting Optim Cutpoints Diagnostic Tests. J Stat Softw. 2014. https://doi.org/10.18637/jss.v061.i08 .
doi: 10.18637/jss.v061.i08
Zhu C, Lian Y, Wang C, Wu P, Li X, Gao Y, et al. Single-cell transcriptomics dissects hematopoietic cell destruction and T-cell engagement in aplastic anemia. Blood. 2021;138:23–33.
pubmed: 33763704
pmcid: 8349468
doi: 10.1182/blood.2020008966
Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36:411–20.
pubmed: 29608179
pmcid: 6700744
doi: 10.1038/nbt.4096
Lopez R, Regier J, Cole MB, Jordan MI, Yosef N. Deep generative modeling for single-cell transcriptomics. Nat Methods. 2018;15:1053–8.
pubmed: 30504886
pmcid: 6289068
doi: 10.1038/s41592-018-0229-2
Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20:163–72.
pubmed: 30643263
pmcid: 6340744
doi: 10.1038/s41590-018-0276-y
Buuren S, van, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1–67.
doi: 10.18637/jss.v045.i03
Aggarwal R, Liao K, Nair R, Ringold S, Costenbader KH. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum. 2009;61:1472–83.
pubmed: 19877103
pmcid: 2859449
doi: 10.1002/art.24827
Lindfors K, Ciacci C, Kurppa K, Lundin KEA, Makharia GK, Mearin ML, et al. Coeliac disease. Nat Rev Dis Prim. 2019;5:3.
pubmed: 30631077
doi: 10.1038/s41572-018-0054-z
Bass GF, Tuscano ET, Tuscano JM. Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014;13:560–4.
pubmed: 24418298
doi: 10.1016/j.autrev.2013.11.010
Lincoln MR, Montpetit A, Cader MZ, Saarela J, Dyment DA, Tiislar M, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet. 2005;37:1108–12.
pubmed: 16186814
doi: 10.1038/ng1647
Zaimoku Y, Patel BA, Kajigaya S, Feng X, Alemu L, Raffo DQ, et al. Deficit of circulating CD19
Hannam-Harris AC, Taylor DS, Nowell PC. Cyclosporin A directly inhibits human B-cell proliferation by more than a single mechanism. J Leukoc Biol. 1985;38:231–9.
pubmed: 3875675
doi: 10.1002/jlb.38.2.231
Ferraro AJ, Drayson MT, Savage COS, MacLennan ICM. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur J Immunol. 2008;38:292–8.
pubmed: 18085668
doi: 10.1002/eji.200737557
Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5. https://www.frontiersin.org/articles/10.3389/fimmu.2014.00520/full .
Manolova I, Dancheva M, Halacheva K. Predominance of IgG1 and IgG3 subclasses of autoantibodies to neutrophil cytoplasmic antigens in patients with systemic lupus erythematosus. Rheumatol Int. 2002;21:227–33.
pubmed: 12036209
doi: 10.1007/s00296-002-0174-2
Saunthararajah Y, Nakamura R, Nam J-M, Robyn J, Loberiza F, Maciejewski JP, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100:1570–4.
pubmed: 12176872
doi: 10.1182/blood.V100.5.1570.h81702001570_1570_1574
Sugimori C, Yamazaki H, Feng X, Mochizuki K, Kondo Y, Takami A, et al. Roles of DRB1 *1501 and DRB1 *1502 in the pathogenesis of aplastic anemia. Exp Hematol. 2007;35:13–20.
pubmed: 17198869
doi: 10.1016/j.exphem.2006.09.002
Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA. 2002;99:7634–9.
pubmed: 12032335
pmcid: 124306
doi: 10.1073/pnas.112202999
Barbieri SS, Petrucci G, Tarantino E, Amadio P, Rocca B, Pesce M, et al. Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice. Thrombosis Haemost. 2015;114:1218–29.
doi: 10.1160/TH14-10-0872
Winkler T, Fan X, Cooper J, Desmond R, Young DJ, Townsley DM, et al. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood. 2019;133:2575–85.
pubmed: 30992268
pmcid: 6566590
doi: 10.1182/blood.2019000478
Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376:1540–50.
pubmed: 28423296
pmcid: 5548296
doi: 10.1056/NEJMoa1613878
Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–9.
pubmed: 22762314
pmcid: 3422737
doi: 10.1056/NEJMoa1200931